Nanoformulations for Ocular Delivery of Drugs - A Patent Perspective
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
Efficient delivery of ocular therapeutics with improved efficacy, enhanced bioavailability, and acceptable patient compliance presents unique challenges. This can be attributed to the presence of protective mechanisms, physicobiological barriers, and structural obstacles in the eye. Nanotherapeutic interventions have been explored extensively over the past few years to overcome these limitations. The present review focusses on the nanoformulations developed for the diagnosis and treatment of various ocular diseases besides providing an in-depth insight into the patents reported for the same.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Recent patents on drug delivery & formulation - 13(2019), 4 vom: 07., Seite 255-272 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dogra, Anmol [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 10.09.2020 Date Revised 10.09.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1872211314666200127101149 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM305819097 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM305819097 | ||
| 003 | DE-627 | ||
| 005 | 20231225122013.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1872211314666200127101149 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1019.xml |
| 035 | |a (DE-627)NLM305819097 | ||
| 035 | |a (NLM)31985387 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dogra, Anmol |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nanoformulations for Ocular Delivery of Drugs - A Patent Perspective |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.09.2020 | ||
| 500 | |a Date Revised 10.09.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a Efficient delivery of ocular therapeutics with improved efficacy, enhanced bioavailability, and acceptable patient compliance presents unique challenges. This can be attributed to the presence of protective mechanisms, physicobiological barriers, and structural obstacles in the eye. Nanotherapeutic interventions have been explored extensively over the past few years to overcome these limitations. The present review focusses on the nanoformulations developed for the diagnosis and treatment of various ocular diseases besides providing an in-depth insight into the patents reported for the same | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Ocular | |
| 650 | 4 | |a nanoemulsions | |
| 650 | 4 | |a nanoformulations | |
| 650 | 4 | |a nanolipid carriers | |
| 650 | 4 | |a nanoparticles | |
| 650 | 4 | |a nanotechnology | |
| 650 | 4 | |a solid lipid carriers. | |
| 700 | 1 | |a Kaur, Kuljeet |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Javed |e verfasserin |4 aut | |
| 700 | 1 | |a Baboota, Sanjula |e verfasserin |4 aut | |
| 700 | 1 | |a Narang, Ramandeep Singh |e verfasserin |4 aut | |
| 700 | 1 | |a Narang, Jasjeet Kaur |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Recent patents on drug delivery & formulation |d 2007 |g 13(2019), 4 vom: 07., Seite 255-272 |w (DE-627)NLM18511380X |x 2212-4039 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2019 |g number:4 |g day:07 |g pages:255-272 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1872211314666200127101149 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2019 |e 4 |b 07 |h 255-272 | ||